✓an ATP-competitive inhibitor of CK2α (IC50 = 2.3 nM) [241]✓reduces p-RPS6 (S235/236) and p-AKT (S129) in imatinib-resistance CML cells without affecting p-BCR-ABL, p-AKT (T308/S473), p-GSK3β (S9), p-p70S6K (T389) and p-ERK1/2 (T202/Y204) [109]✓reduces protein synthesis, induces apoptosis, and overcomes the imatinib-resistance in imatinib-resistant CML cells [109]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.